Application Note: Quantifying NK-mediated cytolysis of glioblastoma in vitro with Maestro Z
6 February 2023
Immunotherapies such as CAR T cells that have shown success in treating liquid tumors have had limited efficacy against solid tumors, including glioblastoma. Natural killer (NK) cells represent a promising approach for solid tumor treatment, and understanding mechanisms of NK-mediated cytotoxicity is important for cell therapy development. In this application note, Axion Biosystems quantifies the kinetics of both antibody-dependent cellular cytotoxicity (ADCC) and CAR NK-mediated cytolysis against glioblastoma cells using the Maestro Z. Kinetics of these mechanisms are assessed across multiple target cell lines and effector:target ratios.